Nu Pharmas

Nu Pharmas is a clinical-stage biopharmaceutical company specializing in the repurposing of established medicines to address neurodegenerative conditions and rare diseases. The company's lead asset, NUP-001, is a high-dose oral formulation of ambroxol currently being evaluated in Phase 3 clinical trials for Parkinson's disease. This program specifically targets the glucocerebrosidase (GBA) pathway to enhance lysosomal function and reduce alpha-synuclein aggregation in the brain. By leveraging the known safety profiles of repurposed drugs, Nu Pharmas aims to significantly accelerate the delivery of disease-modifying therapies to patients. The company operates through strategic partnerships with academic institutions and non-profit organizations, such as Cure Parkinson's, to advance its clinical pipeline.